Search company, investor...

Founded Year

2015

Stage

Unattributed - II | Alive

Total Raised

$3.55M

Last Raised

$1.57M | 3 mos ago

About Gedea Biotech

Gedea Biotech provides biotechnology services specializing in vaginal bacterial and fungal infection treatment. The treatment offers natural substances that restore the vaginal pH level as well as provide physical barrier protection and inhibit biofilm formation. It was founded in 2015 and is based in Lund, Sweden.

Headquarters Location

Scheelevägen 2 Medicon Village

Lund, 223 63,

Sweden

+46 (0) 708 - 91 86 81

Loading...

Loading...

Gedea Biotech Patents

Gedea Biotech has filed 5 patents.

The 3 most popular patent topics include:

  • animal fungal diseases
  • bacteriology
  • microbiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/31/2021

7/11/2023

Vagina, Animal fungal diseases, Microbiology, Bacteriology, Microbiomes

Grant

Application Date

3/31/2021

Grant Date

7/11/2023

Title

Related Topics

Vagina, Animal fungal diseases, Microbiology, Bacteriology, Microbiomes

Status

Grant

Latest Gedea Biotech News

The Swedish femtech company Gedea Biotech completes important clinical trial on vaginal fungal infection

Feb 8, 2024

Gedea Biotech AB Thu, Feb 08, 2024 14:38 CET The study includes 26 patients, all of whom have now commenced treatment with pHyph. Results from the study are expected in the second quarter of 2024. Lund, Sweden, February 8, 2024 The Swedish femtech company Gedea Biotech, which is developing an antibiotic-free treatment for vaginal infections, today announced that all patients in the EpHect study have been included and commenced treatment with pHyph. Results from the study are expected in the second quarter of this year. Vaginal yeast infection affects 75% of all women at some point in their lives. Treatment is usually an over-the-counter cream or suppositories, and if symptoms are severe or recurrent, prescription per oral treatment is available. Globally, there are signs of and concerns about resistance developing against available treatments. Self-diagnose is difficult and studies show that a majority of women who purchase over-the-counter products for the treatment of vaginal yeast infection do not actually have a yeast infection. This leads to over-treatment and the risk of resistance developing. The EpHect study has been conducted at four clinics in Sweden, with a total of 26 patients participating. Patients have been treated with pHyph for six days using vaginal tablets at home. After the treatment period, patients were followed up for 25 days to evaluate treatment effectiveness and whether the infection recurs. The clinics have used internationally applicable criteria for diagnosis and evaluation. "Vaginal fungal infection is very common, and some women suffer from prolonged, recurrent symptoms. The drugs available usually work well, but relapses are common, and there is concern about resistance developing in the future. More treatment options are needed for this patient group," says Helena Kopp-Kallner, Chief Physician in Gynecology, Ph.D., at the Women's Health Clinic at Danderyd Hospital, Stockholm, Sweden, who is the responsible physician for the EpHect study. Annette Säfholm, CEO of Gedea Biotech, comments: "The clinics that have participated in the study have done a fantastic job of including patients and conducting the study. We are also extremely grateful to the patients who have participated and contributed to important research. The purpose of the EpHect study is to confirm the safety and efficacy of pHyph in the treatment of vaginal yeast infection. A product with dual effect in the treatment of bacterial vaginosis and yeast infections would be an ideal treatment for all the women who are unsure of the type of infection causing their symptoms." About the EpHect study An open-labelled study to evaluate Clinical Performance of the Gedea Pessary (pHyph) in Adult Women with Vulvovaginal Candidiasis: 26 women of menstruating age over 18 years with a VVC diagnosis are treated for 6 days (day 0 to day 5) and undergo follow-up visits until day 25. More information about the study can be found here: https://clinicaltrials.gov/ct2/show/NCT05507333?spons=Gedea+Biotech&draw=2&rank=1 About pHyph pHyph is being developed as a vaginal tablet to treat and prevent both vaginal yeast infection and bacterial vaginosis. pHyph has no antimicrobial properties but affects the vaginal environment by lowering pH and dissolving biofilm so that the presence of yeast and bacteria develops in a healthy manner. With the dual effect against both yeast and bacterial infection, the chance of correct self-care increases, leading to reduced use of antimicrobial products and thus reduced resistance development. The naturally occurring active ingredient GDA 001 in pHyph is well-documented and is already approved as a food additive. A clinical healing rate for BV comparable to antibiotics on the market has been shown in two phase 2 studies but with a higher safety profile and without causing secondary VVC infections that occur with antibiotics. For more information Annette Säfholm, CEO Gedea Biotech Phone: +46 708 - 91 86 81 Email: annette.safholm@gedeabiotech.com Phone: +46 70- 791 49 54 Email: ton.berkien@gedeabiotech.com About Gedea Biotech Gedea Biotech is a Swedish, innovative company in women's health developing pHyph, an antibiotic-free product aimed at both treating and preventing bacterial vaginosis. Vaginal infections affect more than 400 million women worldwide each year, and the market is worth over $1.5 billion. Gedea Biotech was founded in 2015 in Lund, Sweden. www.gedeabiotech.com.

Gedea Biotech Frequently Asked Questions (FAQ)

  • When was Gedea Biotech founded?

    Gedea Biotech was founded in 2015.

  • Where is Gedea Biotech's headquarters?

    Gedea Biotech's headquarters is located at Scheelevägen 2, Lund.

  • What is Gedea Biotech's latest funding round?

    Gedea Biotech's latest funding round is Unattributed - II.

  • How much did Gedea Biotech raise?

    Gedea Biotech raised a total of $3.55M.

  • Who are the investors of Gedea Biotech?

    Investors of Gedea Biotech include Jensen Corporate Finance, SAB Corporate Finance, Medtech4Health, Swelife, Horizon 2020 and 6 more.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.